TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16509105

Group type: EXPERIMENTAL
Intervention: Right‐Brain Damaged (RBD) patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study: 15564707

Group type: EXPERIMENTAL
Intervention: Standard plus exercise at a fitness club (2-4 times per week)
Number of subjects: 561

Group type: COMPARATOR
Intervention: National standard alone (control)
Number of subjects: 561
Study: 11773207

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Growth Hormone + Testosterone (GH + T)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) + HRT
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 125
Study: 9561680

Group type: EXPERIMENTAL
Intervention: Cyclosporin (CyA, n = 14)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tacrolimus (n = 13)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prednisone treatment (more prevalent in CyA-treated patients)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy matched controls (n = 20)
Number of subjects: 27
Study: 8079602

Group type: EXPERIMENTAL
Intervention: Blood velocimetry of the fetal descending aorta, umbilical artery and vein, and the maternal arcuate artery using 2.5 MHz pulsed wave Doppler ultrasound; Histological examination of at least five random samples from each placenta
Number of subjects: 37
Study: 2722224

Group type: EXPERIMENTAL
Intervention: Oral hydrocortisone (200 mg/day for 1 week)
Number of subjects: 8
Study: 55717

Group type: EXPERIMENTAL
Intervention: Diazoxide 5 mg/kg/day for 7 days with insulin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo with insulin
Number of subjects: 14
Study: 31878111

Group type: EXPERIMENTAL
Intervention: Nicotine fact sheet
Number of subjects: 756

Group type: COMPARATOR
Intervention: Control messages (bottled water ads)
Number of subjects: 756
Study: 29850571

Group type: EXPERIMENTAL
Intervention: High-flow desflurane (Group I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-flow desflurane (Group II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-flow TIVA (propofol, remifentanil) (Group III)
Number of subjects: 90
Study: 26738470

Group type: EXPERIMENTAL
Intervention: Education on symptoms management based on training modifications
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Exercise program targeting lower limb strengthening and control in addition to education
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Running gait retraining advice in addition to education
Number of subjects: 69

Group type: COMPARATOR
Intervention: All groups (Education, Exercise, Gait retraining)
Number of subjects: 69
Study: 25298894

Group type: EXPERIMENTAL
Intervention: Topical menthol (Biofreeze)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (gel with a menthol scent)
Number of subjects: 10
Study: 22283697

Group type: EXPERIMENTAL
Intervention: Apical negative pressure (ANP) irrigation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Positive pressure
Number of subjects: 70

Group type: COMPARATOR
Intervention: SAF without pecking motion
Number of subjects: 70

Group type: COMPARATOR
Intervention: SAF with pecking motion
Number of subjects: 70
Study: 20302001

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 142

Group type: COMPARATOR
Intervention: Percutaneous surgery
Number of subjects: 142
Study: 17413246

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 0
Study: 16148057

Group type: EXPERIMENTAL
Intervention: Photopheresis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11929416

Group type: EXPERIMENTAL
Intervention: Homes with carpets and older mattresses
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: House dust mite impermeable mattress encasings
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Carpeted floors
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Older homes
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Woollen or synthetic blankets or synthetic quilts
Number of subjects: 616
Study: 10411810

Group type: EXPERIMENTAL
Intervention: Heparin therapy in addition to antimicrobial agents
Number of subjects: 15

Group type: COMPARATOR
Intervention: Antimicrobial therapy alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Women with persistent fever but without computed tomographic evidence of septic pelvic thrombophlebitis
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Women with diagnosed thrombosis
Number of subjects: 15
Study: 7587731

Group type: EXPERIMENTAL
Intervention: Flow cytometric reticulocyte maturity index (RMI)
Number of subjects: 413
Study: 2257800

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus codeine 30 mg
Number of subjects: 204
Study: 6449679

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30246357

Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 147
Study: 27906753

Group type: EXPERIMENTAL
Intervention: pegylated interferon with silymarin
Number of subjects: 70

Group type: COMPARATOR
Intervention: pegylated interferon without silymarin
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: pegylated interferon with or without silymarin
Number of subjects: 70
Study: 25335944

Group type: EXPERIMENTAL
Intervention: Proactive + 4 weeks of medication (Counselor‐initiated intervention)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Reactive + 2 weeks of medication (Participant‐initiated intervention)
Number of subjects: 519
Study: 24305681

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (running at ∼70% maximum aerobic capacity)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-calorie food images after high-intensity exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-calorie food images after high-intensity exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Resting control trial (REST)
Number of subjects: 15
Study: 22607192

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 1168
Study: 19544817

Group type: EXPERIMENTAL
Intervention: Group 1 (AdheSE sealed, gently air-blown, light-cured)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 2 (AdheSE sealed, heavily air-blown, light-cured)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 4 (Not sealed, gently air-blown, light-cured)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 5 (Not sealed, heavily air-blown, light-cured)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 3 (AdheSE sealed, gently air-blown, not light-cured)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group 6 (Not sealed, gently air-blown, not light-cured)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 1 (Duo-Link, AdheSE sealed, gently air-blown, light-cured)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 2 (Duo-Link, AdheSE sealed, heavily air-blown, light-cured)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 4 (Duo-Link, Not sealed, gently air-blown, light-cured)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 5 (Duo-Link, Not sealed, heavily air-blown, light-cured)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group 3 (Duo-Link, AdheSE sealed, gently air-blown, not light-cured)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group 6 (Duo-Link, Not sealed, gently air-blown, not light-cured)
Number of subjects: 90
Study: 17583395

Group type: EXPERIMENTAL
Intervention: Tdap (reduced-antigen-content tetanus, diphtheria, acellular pertussis)
Number of subjects: 319

Group type: COMPARATOR
Intervention: DTaP (diphtheria-tetanus-acellular pertussis)
Number of subjects: 319
Study: 15248204

Group type: EXPERIMENTAL
Intervention: Combination of 3 DMARDs (methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Single DMARD (initially sulfasalazine) with or without prednisolone
Number of subjects: 195
Study: 12587686

Group type: EXPERIMENTAL
Intervention: Bromelain 200 mg per day
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Bromelain 400 mg per day
Number of subjects: 77
Study: 9535138

Group type: EXPERIMENTAL
Intervention: Newer blood-pressure-lowering drugs (such as angiotensin converting enzyme inhibitors and calcium antagonists)
Number of subjects: 64000

Group type: COMPARATOR
Intervention: Newer blood-pressure-lowering treatments
Number of subjects: 64000

Group type: COMPARATOR
Intervention: Older classes of blood-pressure-lowering drugs
Number of subjects: 64000
Study: 7640499

Group type: EXPERIMENTAL
Intervention: Lappaconitine 4 ml
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lappaconitine 8 ml
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lappaconitine 12 ml
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.9% NS 6 ml (Control)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine 2 mg (Control)
Number of subjects: 50
Study: 1325010

Group type: EXPERIMENTAL
Intervention: Reduced doses of lisinopril and sustained release verapamil (group III)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lisinopril alone (group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sustained release verapamil alone (group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrochlorothiazide with guanfacine (group IV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 6307704

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 21
Study: 30311948

Group type: EXPERIMENTAL
Intervention: Trehalose powder with air-polishing device
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sonic device
Number of subjects: 44
Study: 30257191

Group type: EXPERIMENTAL
Intervention: Ultrathin bioresorbable polymer sirolimus-eluting stent (BP SES)
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Thin durable polymer everolimus-eluting stent (DP EES)
Number of subjects: 1334
Study: 26963073

Group type: EXPERIMENTAL
Intervention: Pneumatic unloader brace
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard nonoperative treatment
Number of subjects: 36
Study: 24626106

Group type: EXPERIMENTAL
Intervention: Store-and-Forward (SF) teledermatology
Number of subjects: 192
Study: 22437952

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 46

Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 46
Study: 20804290

Group type: EXPERIMENTAL
Intervention: Item-general practice condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Item-specific practice condition
Number of subjects: 0
Study: 17592479

Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg/day)
Number of subjects: 4325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4325
Study: 17671533

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiation (surgery followed by radiation therapy at 50Gy/5 weeks, 2Gy/fraction, 5 days/week) plus chemotherapy (Leucovorin 300mg/m2 followed by 5-FU 350mg/m2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preoperative radiotherapy (46Gy/4.5 weeks, 2Gy/fraction, 5 days/week) followed by surgery +/- postoperative chemotherapy
Number of subjects: 50
Study: 12786632

Group type: EXPERIMENTAL
Intervention: Esomeprazole, metronidazole and clarithromycin (EMC)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Omeprazole, metronidazole and clarithromycin (OMC)
Number of subjects: 379
Study: 11202417

Group type: EXPERIMENTAL
Intervention: 10 mg gossypol
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 12.5 mg gossypol
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control
Number of subjects: 77
Study: 9465478

Group type: EXPERIMENTAL
Intervention: 9 MU natural interferon alpha for 24 weeks (group A)
Number of subjects: 99

Group type: COMPARATOR
Intervention: 6 MU natural interferon alpha for 24 weeks (group B)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 99
Study: 8364260

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2942407

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg b.i.d.)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 154
Study: 29648642

Group type: EXPERIMENTAL
Intervention: Frontal cerebral thermal therapy (maintained at 14‐16°C)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 106
Study: 26799509

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 24745696

Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg, every 3 weeks for 1 year
Number of subjects: 1343

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1343

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1343
Study: 22920273

Group type: EXPERIMENTAL
Intervention: Flexi-T380(+) IUD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nova-T200 IUD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-intervention group (other post-abortion contraception methods)
Number of subjects: 0
Study: 20959424

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17656661

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined intravenous and intraarterial approach to recanalization
Number of subjects: 0
Study: 16320094

Group type: EXPERIMENTAL
Intervention: STEAM spectroscopy
Number of subjects: 22
Study: 11919227

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (5-FU-based)
Number of subjects: 862

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 862
Study: 7523778

Group type: EXPERIMENTAL
Intervention: celiprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 3066856

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy alone (6,000 rads)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Postoperative radiotherapy combined with CCNU chemotherapy (100 mg/sq m every 6-8 weeks)
Number of subjects: 198
Study: 30371518

Group type: EXPERIMENTAL
Intervention: Targeted Muscle Reinnervation (TMR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard treatment (neuroma excision and burying into muscle)
Number of subjects: 28
Study: 27922029

Group type: EXPERIMENTAL
Intervention: Eluxadoline 75 mg BID
Number of subjects: 2776

Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg BID
Number of subjects: 2776

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2776
Study: 26547229

Group type: EXPERIMENTAL
Intervention: 5% sodium chloride with 0.15% sodium hyaluronate eye drops for 1 month
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group without treatment for edema
Number of subjects: 86
Study: 23441606

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Correlates of 25(OH)D concentrations
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations
Number of subjects: 904
Study: 21454456

Group type: EXPERIMENTAL
Intervention: Co‐trimoxazole prophylaxis continued until 2 years old
Number of subjects: 203

Group type: COMPARATOR
Intervention: Co‐trimoxazole prophylaxis stopped immediately
Number of subjects: 203
Study: 19674956

Group type: EXPERIMENTAL
Intervention: 3-month PAM intervention (n = 51)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group received a single written information brochure with brief general PA recommendations (n = 51)
Number of subjects: 102
Study: 16784956

Group type: EXPERIMENTAL
Intervention: DHEA (100-400 mg/d)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 15382812

Group type: EXPERIMENTAL
Intervention: Forearm/hand splint
Number of subjects: 43

Group type: COMPARATOR
Intervention: Elbow band
Number of subjects: 43
Study: 11751732

Group type: EXPERIMENTAL
Intervention: 0.4 mg sublingual nitroglycerin (NTG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 36
Study: 9420016

Group type: EXPERIMENTAL
Intervention: Combination 5‐FU plus leucovorin (LV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Monthly schedule of 5‐FU/LV (200 mg/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Weekly schedule of 5‐FU/LV (high-dose LV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Racemic commercial formulation of LV
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sequential methotrexate/5‐FU
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous infusion schedules of 5‐FU
Number of subjects: 12
Study: 8305958

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) at a dose of 400 mg/kg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 33
Study: 2849460

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 31894236

Group type: EXPERIMENTAL
Intervention: 200 mg testosterone enanthate/week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31056148

Group type: EXPERIMENTAL
Intervention: Higher vegetable dietary pattern scores
Number of subjects: 987
Study: 27776926

Group type: EXPERIMENTAL
Intervention: With load (4-kg) during 90° shoulder abduction maximal humeral external rotation (90°er)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Without load (NL) during 90° shoulder abduction neutral (90°neutral)
Number of subjects: 25
Study: 25444751

Group type: EXPERIMENTAL
Intervention: ADAMTS13
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HSP27
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: sP‐Selectin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Base Deficit (BD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Heart Rate (HR)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Shock Index (SI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Tissue Oxygen Saturation (StO2)
Number of subjects: 17
Study: 22711752

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg b.i.d.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 22863658

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T vaccine
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Licensed hexavalent control vaccine (Infanrix™ hexa)
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T booster
Number of subjects: 1189
Study: 19423470

Group type: EXPERIMENTAL
Intervention: Sequential intravenous (i.v.) to oral (p.o.) moxifloxacin 400 mg once daily
Number of subjects: 595

Group type: COMPARATOR
Intervention: i.v. ceftriaxone 2 g once daily plus metronidazole 500 mg three times daily, followed by p.o. amoxicillin/clavulanate 625 mg three times daily
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Both treatment groups (moxifloxacin and ceftriaxone/metronidazole)
Number of subjects: 595
Study: 18270944

Group type: EXPERIMENTAL
Intervention: Intrathecal meperidine (15 mg) plus 75 mg of hyperbaric lidocaine 5%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline plus 75 mg of hyperbaric lidocaine 5%
Number of subjects: 80
Study: 15105167

Group type: EXPERIMENTAL
Intervention: GLP-1 (0.9 pmol x kg(‐1) x min(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCK-33 (0.2 pmol x kg(‐1) x min(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GLP-1 plus CCK-33
Number of subjects: 0
Study: 11552922

Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: rabeprazole 20 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: rabeprazole 40 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: CYP2C19 extensive metabolizers
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: CYP2C19 poor metabolizers
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Adverse events in extensive metabolizers
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Adverse events in poor metabolizers
Number of subjects: 102
Study: 9625181

Group type: EXPERIMENTAL
Intervention: In-home comprehensive geriatric assessment and preventive care
Number of subjects: 202
Study: 7946364

Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms/kg intubation dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Maintenance doses of rocuronium
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Reversal of rocuronium-induced neuromuscular block
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis of rocuronium
Number of subjects: 36
Study: 2884682

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29661218

Group type: EXPERIMENTAL
Intervention: Reduced follow-up schedule (4 visits over 3 years)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Standard follow-up schedule (10-13 visits over 5 years)
Number of subjects: 282
Study: 28460629

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg plus Ezetimibe 10 mg daily
Number of subjects: 4650

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4650
Study: 26631004

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both GIK and placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: hs-CRP measured at 12 hours
Number of subjects: 143
Study: 23332608

Group type: EXPERIMENTAL
Intervention: Evidence-based intervention (cognitive behavioral therapy, psychotropic medication or both)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1004